Matt Hitchings,
Assistant Professor
Department:
PHHP-COM BIOSTATISTICS
Business Phone:
(352) 294-1945
Business Email:
mhitchings@ufl.edu
Teaching Profile
Courses Taught
2021-2022,2024
PHC6059 Introduction to Applied Survival Analysis
2023-2024
PHC6937 Special Topics in Public Health
2023-2025
PHC6905 Independent Study
2023-2025
PHC7979 Advanced Research
2025
PHC6940 Master of Public Health Capstone
2025
PHC7980 Research for Doctoral Dissertation
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0003-2327-3557
Areas of Interest
- Clinical Trials Design & Analysis
- Emerging infectious disease
- Infectious Diesease
- Vaccination
Publications
Academic Articles
2025
Analysis methods for covariate-constrained cluster randomized trials with time-to-event outcomes.
BMC medical research methodology.
25(1)
[DOI] 10.1186/s12874-025-02465-w.
[PMID] 39844041.
2025
Coronavirus Disease 2019 Lineages in a Minimally Vaccinated Island Population: Genomic Epidemiology of Severe Acute Respiratory Syndrome Coronavirus 2 in Haiti
The Journal of Infectious Diseases.
231(2):386-391
[DOI] 10.1093/infdis/jiae520.
[PMID] 39440935.
2024
A systematic review of using population-level human mobility data to understand SARS-CoV-2 transmission
Nature Communications.
15(1)
[DOI] 10.1038/s41467-024-54895-7.
[PMID] 39627231.
2024
Confronting Health Misinformation Surrounding COVID-19 Vaccines in the State of Florida.
Journal of general internal medicine.
39(8):1488-1491
[DOI] 10.1007/s11606-024-08726-6.
[PMID] 38499724.
2024
Correction: Effectiveness of a monthly schedule of follow-up for the treatment of uncomplicated severe acute malnutrition in Sokoto, Nigeria: A cluster randomized crossover trial.
PLoS medicine.
21(3)
[DOI] 10.1371/journal.pmed.1004370.
[PMID] 38507664.
2024
Corrigendum to “Extensive transmission of SARS-CoV-2 BQ.1* variant in a population with high levels of hybrid immunity: A prevalence survey” [International Journal of Infectious Diseases 139 (2024) 159-167].
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
141
[DOI] 10.1016/j.ijid.2024.02.007.
[PMID] 38452689.
2024
Effectiveness of the fourth dose of COVID-19 vaccines against severe COVID-19 among adults 40 years or older in Brazil: a population-based cohort study.
Lancet regional health. Americas.
34
[DOI] 10.1016/j.lana.2024.100755.
[PMID] 38737773.
2024
Extensive transmission of SARS-CoV-2 BQ.1* variant in a population with high levels of hybrid immunity: A prevalence survey.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
139:159-167
[DOI] 10.1016/j.ijid.2023.11.039.
[PMID] 38070701.
2024
Overestimation of Severe Acute Respiratory Syndrome Coronavirus 2 Household Transmission in Settings of High Community Transmission: Insights From an Informal Settlement Community in Salvador, Brazil
Open Forum Infectious Diseases.
11(3)
[DOI] 10.1093/ofid/ofae065.
[PMID] 38516384.
2024
Severity-dependent test-seeking behaviors and test-negative designs: impact on estimated vaccine effectiveness and utility of analytic and design choices
American Journal of Epidemiology.
[DOI] 10.1093/aje/kwae303.
2023
A Mixture Model for Estimating SARS-CoV-2 Seroprevalence in Chennai, India.
American journal of epidemiology.
192(9):1552-1561
[DOI] 10.1093/aje/kwad103.
[PMID] 37084085.
2023
Accounting for assay performance when estimating the temporal dynamics in SARS-CoV-2 seroprevalence in the U.S.
Nature Communications.
14(1)
[DOI] 10.1038/s41467-023-37944-5.
[PMID] 37076502.
2023
Dynamics of Anti-influenza Mucosal IgA Over a Season in a Cohort of Individuals Living or Working in a Long-term Care Facility
The Journal of Infectious Diseases.
228(4):383-390
[DOI] 10.1093/infdis/jiad029.
[PMID] 36740584.
2023
Evidence of leaky protection following COVID-19 vaccination and SARS-CoV-2 infection in an incarcerated population
Nature Communications.
14(1)
[DOI] 10.1038/s41467-023-40750-8.
[PMID] 37598213.
2023
Household Transmission Dynamics of Seasonal Human Coronaviruses.
The Journal of infectious diseases.
227(9):1104-1112
[DOI] 10.1093/infdis/jiac436.
[PMID] 36350773.
2023
Previous Dengue Infection among Children in Puerto Rico and Implications for Dengue Vaccine Implementation.
The American journal of tropical medicine and hygiene.
109(2):413-419
[DOI] 10.4269/ajtmh.23-0091.
[PMID] 37308104.
2023
Use of Whole-Genome Sequencing to Estimate the Contribution of Immune Evasion and Waning Immunity on Decreasing COVID-19 Vaccine Effectiveness.
The Journal of infectious diseases.
227(5):663-674
[DOI] 10.1093/infdis/jiac453.
[PMID] 36408616.
2022
Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case–control analysis
PLOS Medicine.
19(12)
[DOI] 10.1371/journal.pmed.1004136.
[PMID] 36454733.
2022
Change in covid-19 risk over time following vaccination with CoronaVac: test negative case-control study.
BMJ (Clinical research ed.).
377
[DOI] 10.1136/bmj-2022-070102.
[PMID] 35697361.
2022
Cost-effectiveness of monthly follow-up for the treatment of uncomplicated severe acute malnutrition: An economic evaluation of a randomized controlled trial.
PLOS global public health.
2(12)
[DOI] 10.1371/journal.pgph.0001189.
[PMID] 36962786.
2022
Effectiveness of a monthly schedule of follow-up for the treatment of uncomplicated severe acute malnutrition in Sokoto, Nigeria: A cluster randomized crossover trial
PLOS Medicine.
19(3)
[DOI] 10.1371/journal.pmed.1003923.
[PMID] 35231024.
2022
Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil
Nature Communications.
13(1)
[DOI] 10.1038/s41467-022-33169-0.
[PMID] 36202800.
2022
Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.
The Lancet. Infectious diseases.
22(6):791-801
[DOI] 10.1016/S1473-3099(22)00140-2.
[PMID] 35366959.
2022
EVITA Dengue: a cluster-randomized controlled trial to EValuate the efficacy of Wolbachia-InfecTed Aedes aegypti mosquitoes in reducing the incidence of Arboviral infection in Brazil.
Trials.
23(1)
[DOI] 10.1186/s13063-022-05997-4.
[PMID] 35236394.
2022
Structural factors associated with SARS-CoV-2 infection risk in an urban slum setting in Salvador, Brazil: A cross-sectional survey
PLOS Medicine.
19(9)
[DOI] 10.1371/journal.pmed.1004093.
[PMID] 36074784.
2022
Use of Recently Vaccinated Individuals to Detect Bias in Test-Negative Case-Control Studies of COVID-19 Vaccine Effectiveness.
Epidemiology (Cambridge, Mass.).
33(4):450-456
[DOI] 10.1097/EDE.0000000000001484.
[PMID] 35384900.
2021
Change in COVID-19 risk over time following vaccination with CoronaVac: A testnegative case-control study.
medRxiv : the preprint server for health sciences.
[DOI] 10.1101/2021.12.23.21268335.
[PMID] 34988559.
2021
Effect of specific non-pharmaceutical intervention policies on SARS-CoV-2 transmission in the counties of the United States.
Nature communications.
12(1)
[DOI] 10.1038/s41467-021-23865-8.
[PMID] 34117244.
2021
Effectiveness of ChAdOx1 vaccine in older adults during SARS-CoV-2 Gamma variant circulation in São Paulo
Nature Communications.
12(1)
[DOI] 10.1038/s41467-021-26459-6.
[PMID] 34711813.
2021
Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study.
Lancet regional health. Americas.
1
[DOI] 10.1016/j.lana.2021.100025.
[PMID] 34386791.
2021
Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study.
BMJ (Clinical research ed.).
374
[DOI] 10.1136/bmj.n2015.
[PMID] 34417194.
2021
Risk Factors for Healthcare Personnel Infection With Endemic Coronaviruses (HKU1, OC43, NL63, 229E): Results from the Respiratory Protection Effectiveness Clinical Trial (ResPECT).
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
73(11):e4428-e4432
[DOI] 10.1093/cid/ciaa900.
[PMID] 32645144.
2021
The Usefulness of the Test-Positive Proportion of Severe Acute Respiratory Syndrome Coronavirus 2 as a Surveillance Tool.
American journal of epidemiology.
190(7):1396-1405
[DOI] 10.1093/aje/kwab023.
[PMID] 33576387.
2020
A mixture model to assess the the immunogenicity of an oral rotavirus vaccine among healthy infants in Niger.
Vaccine.
38(51):8161-8166
[DOI] 10.1016/j.vaccine.2020.10.079.
[PMID] 33162202.
2020
A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity.
Nature communications.
11(1)
[DOI] 10.1038/s41467-020-18450-4.
[PMID] 32943637.
2020
Ensemble forecast modeling for the design of COVID-19 vaccine efficacy trials.
Vaccine.
38(46):7213-7216
[DOI] 10.1016/j.vaccine.2020.09.031.
[PMID] 33012602.
2020
Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013-2016 West Africa Ebola outbreak in Guinea.
Vaccine.
38(31):4877-4884
[DOI] 10.1016/j.vaccine.2020.04.066.
[PMID] 32499066.
2019
Analysis of a meningococcal meningitis outbreak in Niger – potential effectiveness of reactive prophylaxis
PLOS Neglected Tropical Diseases.
13(3)
[DOI] 10.1371/journal.pntd.0007077.
[PMID] 30856166.
2019
Analyzing Vaccine Trials in Epidemics With Mild and Asymptomatic Infection.
American journal of epidemiology.
188(2):467-474
[DOI] 10.1093/aje/kwy239.
[PMID] 30329134.
2019
Linear growth faltering and the role of weight attainment: Prospective analysis of young children recovering from severe wasting in Niger.
Maternal & child nutrition.
15(4)
[DOI] 10.1111/mcn.12817.
[PMID] 30903806.
2018
Competing Effects of Indirect Protection and Clustering on the Power of Cluster-Randomized Controlled Vaccine Trials.
American journal of epidemiology.
187(8):1763-1771
[DOI] 10.1093/aje/kwy047.
[PMID] 29522080.
2018
Impact of stochastically generated heterogeneity in hazard rates on individually randomized vaccine efficacy trials.
Clinical trials (London, England).
15(2):207-211
[DOI] 10.1177/1740774517752671.
[PMID] 29374974.
2018
Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt: A 3-arm, open-label, cluster-randomized trial
PLOS Medicine.
15(6)
[DOI] 10.1371/journal.pmed.1002593.
[PMID] 29944651.
2017
Ciprofloxacin for contacts of cases of meningococcal meningitis as an epidemic response: study protocol for a cluster-randomized trial.
Trials.
18(1)
[DOI] 10.1186/s13063-017-2028-y.
[PMID] 28646924.
2017
Using simulation to aid trial design: Ring-vaccination trials.
PLoS neglected tropical diseases.
11(3)
[DOI] 10.1371/journal.pntd.0005470.
[PMID] 28328984.
Presentations
2023-09-13
Vaccine Effectiveness Studies (Virtual), 2023: Analysis of observational vaccine effectiveness studies (oral presentation, invited)
International
/
Invited.
Lecture.
2024-05-02
Using surveillance data, serology, and age to uncover infectious disease dynamics and mechanisms
National
/
Invited.
Lecture.
2024-05-12
Novel approaches to control mosquito-borne diseases
State
/
Invited.
Lecture.
Grants
May 2024
ACTIVE
Recurrence of Cholera in Haiti: Exploration of Contributing Factors and Intervention Strategies
Role: Project Manager
Funding: NATL INST OF HLTH NIAID
Sep 2023
ACTIVE
Atlantic Coast Center for Infectious Disease Dynamics and Analytics
Role: Principal Investigator
Funding: UNIV OF NORTH CAROLINA CHAPEL HILL
via CTRS FOR DISEASE CONTROL AND PREVENTION
Feb 2023
ACTIVE
Immunological drivers of the transition from epidemicity to endemicity of SARS-CoV-2 in a high transmission LMIC setting
Role: Principal Investigator
Funding: YALE UNIV
via NATL INST OF HLTH NIAID
Apr 2022
– Mar 2024
RAPID: Statistical inference of incidence of SARS-CoV-2 in the US using multiple data streams to identify levels of immunity and the impact of non-pharmaceutical interventions
Role: Co-Project Director/Principal Investigator
Funding: NATL SCIENCE FOU
Mar 2022
– Dec 2023
Estimating the incidence of dengue in travelers from non-endemic countries
Role: Co-Investigator
Funding: Merck Sharp & Dohme
Jan 2022
ACTIVE
IPA for Matthew Hitchings 2022
Role: Principal Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Aug 2021
– Jul 2023
Design and Analysis of Vaccine Trials for Emerging Infectious Disease Threats
Role: Co-Investigator
Funding: EMORY UNIV
via NATL INST OF HLTH NIAID
Apr 2021
– Mar 2025
Human mobility models to forecast disease dynamics and the effectiveness of public health interventions
Role: Principal Investigator
Funding: JOHNS HOPKINS BLOOMBERG SCHOOL PUB HLTH
via NATL INST OF HLTH NIAID
May 2020
– Apr 2025
Forecasting trajectories of HIV transmission networks with a novel phylodynamic and deep learning framework
Role: Project Manager
Funding: NATL INST OF HLTH NIAID
Feb 2020
ACTIVE
VTEU 17-0111 Tasks B-D
Role: Principal Investigator
Funding: EMORY UNIV
via NATL INST OF HLTH NIAID
Contact Details
Phones:
- Business:
- (352) 294-1945
Emails:
- Business:
- mhitchings@ufl.edu
Addresses:
- Business Mailing:
-
PO BOX 117450
GAINESVILLE FL 326117450